<DOC>
	<DOCNO>NCT00458250</DOCNO>
	<brief_summary>Many patient suffer various malignant non-malignant disease need hematopoietic stem cell transplantation healthy person . In majority case match related unrelated donor . Some researcher perform transplantation semi-matched ( haploidentical ) related donor relatively good result . Chinese researcher perform kind transplantation use CAMPATH-1H report indicate good result . Chinese population homogenous genetic background Iranians . In project , go study feasibility method haploidentical transplantation Iranian patient .</brief_summary>
	<brief_title>Feasibility Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H</brief_title>
	<detailed_description>Haploidentical hematopoietic stem cell transplantation important therapeutic intervention treatment genetic disorder hematological malignancy . In majority case , match relate unrelated donor . Haploidentical hematopoietic stem cell transplantation promise alternative critical case . To avoid severe graft versus host disease ( GVHD ) , two type T cell depletion ( TCD ) use : total TCD partial TCD . Total TCD disadvantage increase rate rejection relapse , increased rate infection due delay immune reconstitution . Partial TCD do vivo and/or vitro method . In haploidentical transplantation , donor partial TCD ( ex vivo TCD ) without recipient TCD increase rate rejection prevent severe GVHD successfully . In vivo TCD partial depletion donor recipient T cell do haploidentical transplantation good result ( extent inferior full match transplantation ) use CAMPATH , ATG , etc . Most study perform Chinese Japanese population homogenous genetic background population . In order study feasibility kind transplantation Iranian patient , define project perform haploidentical hematopoietic stem cell transplantation use vivo CAMPATH-1H .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA RECIPIENT : ( follow ) Ages 550 year Acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) Second remission ( CR2 ) standard risk patient CR1 case highrisk feature ( poor cytogenetic change secondary myelodysplastic syndrome ) Unavailability HLA identical relate donor match unrelated donor . Unavailability therapeutic intervention prolongs patient survival . Lack active infection . No history allergy CAMPATH . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian.. Social intellectual competency patient his/her family follow medical recommendation . INCLUSION CRITERIA DONOR : The donor must haploidentical recipient : In order priority , sibling identical paternal HLA haplotype patient , offspring ( female patient appropriate sibling ) , mother . Possibly , good donor recipient blood group sex.. Possibly , good female donor multiparous . Weight great equal 18 kg . Age 2 60 year old . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . Negative twoway WBC crossmatch recipient . EXCLUSION CRITERIA RECIPIENT : ( ANY OF THE FOLLOWING ) Major anticipate illness organ failure incompatible survival transplantation . Severe psychiatric illness . Mental deficiency sufficiently severe make compliance transplantation procedure unlikely make informed consent impossible . Positive pregnancy test woman childbearing age . HIV positive Active infection Left ventricular ejection fraction le 40 % AST/SGOT great 20 x ULN ( CTCAE grade IV v3.0 ) Bilirubin great 10 x ULN ( CTCAE grade IV v3.0 ) Creatinine great 6 x ULN ( CTCAE grade IV v 3.0 ) Occurrence allergy symptom sign CAMPATH infusion . EXCLUSION CRITERIA DONOR : ( ANY OF THE FOLLOWING ) Pregnant lactate Unfit receive filgrastim ( GCSF ) undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) Sickling hemoglobinopathy include HbSS , HbAS , HbSC HBsAg HIV positive Active infection CMV positive ( CMV negative recipient ) Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely make informed consent impossible Contraindication general anesthesia .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Haploidentical</keyword>
	<keyword>Hematologic Neoplasms</keyword>
	<keyword>human , Bone Marrow</keyword>
	<keyword>Granulocyte Colony-stimulating Factor</keyword>
	<keyword>CAMPATH</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>10 . Eligibility</keyword>
</DOC>